AbCellera Biologics (NASDAQ:ABCL) vs. Cerebain Biotech (OTCMKTS:CBBT) Financial Comparison

Cerebain Biotech (OTCMKTS:CBBT) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Cerebain Biotech and AbCellera Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cerebain Biotech	N/A	N/A	N/A
AbCellera Biologics	-463.77%	-13.40%	-10.44%

Analyst Ratings

This is a summary of current ratings and target prices for Cerebain Biotech and AbCellera Biologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerebain Biotech	0	0	0	0	N/A
AbCellera Biologics	0	1	5	0	2.83

AbCellera Biologics has a consensus price target of $14.20, suggesting a potential upside of 444.06%. Given AbCellera Biologics’ higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Cerebain Biotech.

Insider and Institutional Ownership

61.4% of AbCellera Biologics shares are owned by institutional investors. 32.5% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cerebain Biotech and AbCellera Biologics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerebain Biotech	N/A	N/A	N/A	N/A	N/A
AbCellera Biologics	$33.05 million	23.22	-$146.40 million	($0.52)	-5.02

Cerebain Biotech has higher earnings, but lower revenue than AbCellera Biologics.

Summary

AbCellera Biologics beats Cerebain Biotech on 5 of the 8 factors compared between the two stocks.

About Cerebain Biotech

Cerebain Biotech Corp. is a biomedical company, which engages in the creation and clinical development of a minimally invasive implantable device. It focuses on the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The company was founded on December 18, 2007 and is headquartered in Costa Mesa, CA.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.